(4-吡咯-1-苯基)-乙酸 | 22048-71-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 中文名称: (4-吡咯-1-苯基)-乙酸
• 中文别名: [4-(1H-吡咯-1-基)苯基]乙酸；2-[4-(1-吡咯基)苯基]乙酸；(4-吡咯-1-基-苯基)-乙酸；乙酸,(对-(1-吡咯基)苯基)-；苯乙酸,4-(1H-吡咯-1-基)-；2-(4-吡咯-1-基苯基)乙酸；(对-(1-吡咯基)苯基)乙酸
• 英文名称: N-(4-carboxymethenephenyl)pyrrole
• 英文别名: acido 4-(pirrol-1-il)fenilacetico；(4-pyrrol-1-yl-phenyl)-acetic acid；p-(1-Pyrryl)-phenylessigsaeure；2-(4-pyrrol-1-ylphenyl)acetic acid
• CAS: 22048-71-1
• 化学式: C₁₂H₁₁NO₂
• mdl: MFCD01672789
• 分子量: 201.225
• InChiKey: KCZGWRZYJZGMQW-UHFFFAOYSA-N

物化性质

• 熔点：
  180-182 °C(Solv: benzene (71-43-2))
• 沸点：
  372.7±25.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)
• 溶解度：
  >30.2 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  (4-吡咯-1-苯基)-乙酸 在 lithium aluminium tetrahydride 、 N,N'-羰基二咪唑 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 Phenyl-[2-(4-pyrrol-1-yl-phenyl)-ethyl]-amine
  参考文献：
  名称：

  Stefancich; Artico; Corelli, Farmaco, Edizione Scientifica, 1984, vol. 39, # 9, p. 752 - 764

  摘要：

  DOI：
• 作为产物：
  描述：

  ethyl ester of 4-pyrrol-1-ylphenylacetic acid 以82%的产率得到
  参考文献：
  名称：

  MASSA, S.;STEFANCICH, G.;ARTICO, M.;CORELLI, F.;BAGLIONI, A.;ANGELUCCI, L+, FARMACO. ED. SCI., 1983, 38, N 2, 90-100

  摘要：

  DOI：

文献信息

• [EN] PHENYLACETAMIDO- PYRAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS<br/>[FR] DERIVES PHENYLACETAMIDO-PYRAZOLE ET LEUR UTILISATION COMME AGENTS ANTITUMORAUX
  申请人：PHARMACIA ITALIA SPA

  公开号：WO2002048114A1

  公开（公告）日：2002-06-20

  Phenylacetamido-pyrazoles of Formula (I) and, more particularly, N-(5-cycloalkyl-1H-pyrazol-3-yl) phenylacetamido derivatives, optionally further substituted as reported in the description; or pharmaceutically acceptable salts thereof; are useful in the treatment of cell proliferative disorders, e.g.cancer, associated with an altered cell cycle dependent kinase activity. Formula (I).

  公式（I）中的苯乙酰胺基吡唑，更具体地说，是N-(5-环烷基-1H-吡唑-3-基)苯乙酰胺衍生物，可以进一步按照描述进行取代的衍生物；或其药学上可接受的盐；在治疗细胞增殖性疾病，例如与改变的细胞周期依赖性激酶活性相关的癌症中有用。 公式（I）。
• Amide derivatives of 2-(p-aminobenzyl)-butyric acid and esters thereof
  申请人：Medosan Industrie Biochimiche Riunite S.p.A.

  公开号：US04666936A1

  公开（公告）日：1987-05-19

  Amide derivatives of 2-(p-aminobenzyl)-butyric acid and esters thereof having a hypolipidemizing and hypocholesterolemizing pharmaceutical activity and their preparation are described. Included are compounds of the formula ##STR1## wherein R and R' together represent the group ##STR2## or the group ##STR3## and R" is hydrogen or a 1 to 6 carbon alkyl group.

  本文描述了具有降血脂和降胆固醇药理活性的2-(对氨基苯基)-丁酸和其酯的酰胺衍生物及其制备方法。其中包括公式##STR1##的化合物，其中R和R'一起代表##STR2##或##STR3##，R"是氢或1至6碳的烷基。
• Phenylacetamido-pyrazole derivatives and their use as antitumor agents
  申请人：——

  公开号：US20040019046A1

  公开（公告）日：2004-01-29

  Phenylacetamido-pyrazoles and, more particularly, N-(5-cycloalkyl-1H-pyrazol-3-yl)phenylacetamido derivatives, optionally further substituted as reported in the description; or pharmaceutically acceptable salts thereof; are useful in the treatment of cell proliferative disorders, e.g. cancer, associated with an altered cell cycle dependent kinase activity.

  苯乙酰胺基吡唑，更具体地说，是N-(5-环烷基-1H-吡唑-3-基)苯乙酰胺衍生物，可选择性地进一步取代，如描述所述；或其药学上可接受的盐；在治疗与细胞周期依赖性激酶活性改变相关的细胞增殖性疾病，例如癌症方面有用。
• Design, Synthesis, and Biological Evaluation of <i>N</i>-Carboxyphenylpyrrole Derivatives as Potent HIV Fusion Inhibitors Targeting gp41
  作者：Kun Liu、Hong Lu、Ling Hou、Zhi Qi、Cátia Teixeira、Florent Barbault、Bo-Tao Fan、Shuwen Liu、Shibo Jiang、Lan Xie

  DOI：10.1021/jm800869t

  日期：2008.12.25

  On the basis of the structures of small-molecule hits targeting the HIV-1 gp41, N-(4-carboxy-3-hydi-oxy)plieiiyl-2,5-dimethylpyl-role (2, NB-2), and N-(3-carboxy-4-chloro)phenylpyrrole (A(1), NB-64), 42 N-carboxyphenylpyrrole derivatives in two categories (A and B series) were designed and synthesized. We found that I I compounds exhibited promising anti-HIV-1 activity at micromolar level and their antiviral activity was correlated with their inhibitory activity on gp41 six-helix bundle formation, suggesting that these compounds block HIV fusion and entry by disrupting gp41 core formation. The structure-activity relationship and molecular docking analysis revealed that the carboxyl group Could interact with either Arg579 or Lys574 to form salt bridges and two methyl groups on the pyrrole ring were favorable for interaction with the residues in gp41 pocket. The most active compound, N-(3-carboxy-4-hydroxy)phenyl-2,5-dimethylpyrrole (A(12)), partially occupied the deep hydrophobic pocket, suggesting that enlarging the molecular size of A(12) could improve its binding affinity and anti-HIV-1 activity for further development as a small-molecule HIV fusion and entry inhibitor.
• Amide derivatives of 2-(p-aminobenzyl)-butyric acid and esters thereof having hypolipidemizing activity
  申请人：Medosan Industrie Biochimiche Riunite S.r.l.

  公开号：EP0172147B1

  公开（公告）日：1992-06-03